Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3
Herrera-Restrepo O, Sweeney C, Mond T, Davenport E, Wang J, Marshall GS. Nurse practitioners' and physician assistants' knowledge, attitudes, and practices regarding meningococcal vaccination for healthy adolescents and young adults in the United States. J Nurse Pract. 2024 Jan;20(1):104793. doi: 10.1016/j.nurpra.2023.104793
Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1
Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8
Ghaswalla P, Davis K, Sweeney C, Davenport E, Trofa A, Herrera-Restrepo O, Buck PO. Health care providers' knowledge, practices, and barriers to hepatitis vaccination guidelines. J Nurse Pract. 2022 Feb 16;18:403-10.
Camprodon-Rosanas E, Pujol J, Martínez-Vilavella G, Blanco-Hinojo L, Medrano-Martorell S, Batlle S, Forns J, Ribas-Fito N, Dolz M, Sunyer J. Brain structure and function in school-aged children with sluggish cognitive tempo symptoms. J Am Acad Child Adolesc Psychiatry. 2019 Feb;58(2):256-96. doi: 10.1016/j.jaac.2018.09.441
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Allan JS, Kanda P, Kennedy RC, Cobb EK, Anthony MS, Eichberg JW. Isolation and characterization of simian immunodeficiency virus from two subspecies of African green monkeys. Aids Res Hum Retrovir. 1990 Mar;6(3):275-85.